# Escalon Medical Reports FY 2026 Net Income of $4.01 Million on Stronger Product Sales

- URL: https://stocks.freetheai.org/news/escalon-medical-reports-fy-2026-net-income-of-4-01-million-on-stronger-product-a05291
- Published: 2026-10-13T20:05:01Z
- Category: earnings; sentiment: bullish; impact: medium
- Symbols: [OTC:ESMC](https://stocks.freetheai.org/symbols/OTC-ESMC)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

Escalon Medical Corp. (OTC:ESMC) reported its full-year 2026 financial results, posting net income of $4.01 million, or $0.27 per diluted share. Total net revenues grew 5.7% to $12.74 million for the fiscal year. The earnings increase was primarily driven by higher sales of Sonomed products and services, alongside a significant pre-tax gain from selling its AXIS software asset. Shares of the company rose 9.93% to $0.165 following the announcement.

The company strengthened its overall operational profile through expanding overseas demand and strategic asset monetization. International sales grew to account for 46.4% of total revenue. Additionally, the sale of AXIS software generated $3.0 million in overall value and $2.8 million in cash receipts, providing a substantial capital cushion. Declines in Trek and AXIS product lines were successfully countered by Sonomed performance, while overall research and development expenses dropped 33.5% due to reduced AXIS consulting costs.

Moving forward, investors will be monitoring whether Escalon Medical can sustain organic revenue growth in its core ultrasound and Sonomed divisions without the one-time tailwind from software sales. Market participants will also watch how the reallocation of research and development funds toward ultrasound technology development translates into long-term commercial products and market expansion.

## Key points

- Full-year 2026 revenue increased 5.7% to $12.74 million, supported by stronger Sonomed product and service sales.
- Net income reached $4.01 million, or $0.27 per diluted share, bolstered by a one-time gain from an asset sale.
- Escalon Medical sold its AXIS software for $3.0 million, bringing in $2.8 million in cash and a pre-tax gain.
- International sales rose to represent 46.4% of total revenue due to higher demand outside the U.S.
- Research and development spending decreased by 33.5% while investments shifted toward ultrasound development.

## Questions and answers

### What were Escalon Medical's full-year 2026 financial results?

Escalon Medical reported full-year 2026 revenue of $12.74 million, up 5.7% from the prior year, and net income of $4.01 million, or $0.27 per diluted share.

### What drove Escalon Medical's revenue and earnings growth in fiscal 2026?

Growth was driven by higher Sonomed product and service sales, increased international demand representing 46.4% of revenue, and a significant pre-tax gain from selling AXIS software for $3.0 million.

### How did Escalon Medical's research and development spending change in 2026?

Research and development expenses dropped 33.5% due to lower AXIS consulting activity, even as the company increased investments in ultrasound technology development.